Live Breaking News & Updates on The national medical products administration of china

Stay updated with breaking news from The national medical products administration of china . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

China , Peking , Beijing , Jun-guo , National-medical-products-administration-of-china , Shanghai-junshi-biosciences-co-ltd , University-cancer-hospital , International-metastatic-renal-cell-carcinoma-database-consortium , National-medical-products-administration , Peking-university-cancer-hospital , News , Global-oncology